The final piece of the jigsaw is the FDA itself, and although it updated guidance on adaptive clinical trials last October, Harris would still like to see more leadership from the regulator so ...
The global clinical trials market has emerged as a vital cornerstone of the healthcare sector, driven by an ever-increasing ...
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...
As we continue to discuss and tackle the problem of underrepresentation in clinical trials, we are also expanding our scope of involvement and inclusivity. The conversations are becoming broader ...
The study will measure the impact of Cognixion's novel combination of BCI, AI and AR technology on the ability of amyotrophic lateral sclerosis ...
The integration of Artificial Intelligence (AI) and Machine Learning (ML) in clinical trial statistical programming has ...
Teams must work together with technology solutions and optimize integration to unlock their full potential. Clinical trials ...
As the number of clinical trials in DLBCL exploring novel MRD-directed ... use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ is CE-marked ...
Cognixion clinical trial findings are expected to refine the ... ALS Association mission by expediting the commercialization of adaptive/assistive technologies, medical devices, diagnostics ...
The enhanced assay was previously made available for research ... clinical sensitivity without compromising our unparalleled specificity,” said Susan Bobulsky, chief commercial officer, MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback